Kenvue Inc., a subsidiary of Johnson & Johnson, operates globally in the consumer health sector. With a focus on Self Care, Skin Health and Beauty, and Essential Health, Kenvue offers well-known brands like Tylenol and Neutrogena. The stock is evaluated through various metrics, reflecting its stability and growth potential in the defensive sector.
The fundamental data shows Kenvue Inc. has a moderate overall rating. Here are its detailed scores across different evaluation categories:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
The historical data provides insights into the company's past performance and trends:
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-06-20 | 2 | 3 | 3 | 4 | 2 | 1 | 1 |
| 2025-06-19 | 0 | 3 | 3 | 4 | 2 | 1 | 1 |
Analyst predictions depict the stock's potential with a consensus centered around stability.
| High | Low | Median | Consensus |
|---|---|---|---|
| $29 | $23 | $26 | $26 |
Analyst recommendations provide further insights into the stock's outlook:
| Recommendation | Count | Visualization |
|---|---|---|
| Buy | 4 | |
| Hold | 7 | |
| Sell | 0 |
Despite being a newer player, Kenvue Inc. holds a steady position in the consumer health industry, backed by strong brands. The stock shows moderate growth potential with room for improvement in financial metrics. Analysts suggest a hold strategy, signaling a prudent approach for investors. However, careful monitoring of market trends and company's strategic decisions is essential to leverage any upcoming opportunities.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.